Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK-Reference-Cited by-同舟云学术

Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK

Published:2019-12 Issue:12 Volume:123 Page:1244-1250
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Rickard Emily,Ozieranski Piotr,Mulinari Shai^ORCID

Funder

Swedish Research Council for Health, Working Life and Welfare

Publisher

Elsevier BV

Subject

Health Policy

Reference48 articles.

1. Involving stakeholders in health care decisions–the experience of the National Institute for Clinical Excellence (NICE) in England and Wales;Culyer;Healthc Q,2005

2. Criteria to be fulfilled by patient, consumer and healthcare professional organisations involved in European Medicines Agency (EMA) activities;EMA,2018

3. Patients involved in NICE (PIN);NICE,2018

4. The added value of patient organisations;European Patients Forum,2013

5. The public shaping of medical research: patient associations, health movements and biomedicine;Wehling,2014

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does the transparency of sustainability reports matter? A quantitative assessment;Corporate Social Responsibility and Environmental Management;2024-08-21

2. Broken beyond repair: self regulation of industry payments to clinicians and hospitals;BMJ;2024-07-12

3. Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019: An observational study;Health Policy and Technology;2024-06

4. Profit and Prudence: Navigating Psychedelic Commercialization Through Lessons from the Prescription Opioid Crisis;Health Policy;2023-12

5. Mapping the Donations of Pharma Companies in Greece: The Case of Scientific Societies;International Journal of Non-Profit Sector Empowerment;2023-05-06